Compassionate use, named patienthttps://legemiddelverket.no/english/import-wholesaling-and-retailing/compassionate-use-named-patient-norwegian-godkjenningsfritakCompassionate use, named patientIn order to use medicines without Market Authorisation (MA) in Norway, prescribers have to apply for compassionate use, named patient (in Norwegian: Godkjenningsfritak).1720
Dispensing regulations (utleveringsbestemmelser)https://legemiddelverket.no/english/import-wholesaling-and-retailing/dispensing-regulations-utleveringsbestemmelserDispensing regulations (utleveringsbestemmelser)NOMA may determine that a drug will be subject to dispensing regulation (1). The pharmacy has a duty to ensure that the requirements for dispensing are met for these medicinal products (2).421NOMA may determine that a drug will be subject to dispensing regulation. The pharmacy has a duty to ensure that the requirements for dispensing are met for these medicinal products.
Import of medicinal products for clinical studies in Norwayhttps://legemiddelverket.no/english/import-wholesaling-and-retailing/import-of-medicinal-products-for-clinical-studies-in-norwayImport of medicinal products for clinical studies in NorwayGeneral guideline regarding persission to import medicinal products for clinical studies in Norway. The guideline also covers the permission to export such products.1498
Importing medicines for personal usehttps://legemiddelverket.no/english/import-wholesaling-and-retailing/importing-medicines-for-personal-useImporting medicines for personal useDifferent rules regarding import of medicines for personal use in the form of consignments and import of medicines when bringing them with you.1616
Procedure for release of blood products and vaccines to the Norwegian markethttps://legemiddelverket.no/english/import-wholesaling-and-retailing/procedure-for-release-of-blood-products-and-vaccines-to-the-norwegian-marketProcedure for release of blood products and vaccines to the Norwegian marketThe Norwegian Medicines Agency follows the EC administrative procedure for Official control authority batch release. 422
WDA Holders within the EU/EEA – requirements for the conduct of wholesaler activities with medicinal products in Norwayhttps://legemiddelverket.no/import-og-salg/import-og-grossistvirksomhet/grossisttillatelse/wda-holders-within-the-eueea-requirements-for-the-conduct-of-wholesaler-activities-with-medicinal-products-in-norwayWDA Holders within the EU/EEA – requirements for the conduct of wholesaler activities with medicinal products in NorwayWholesaling of medicinal products in Norway based on a wholesaler distribution authorization (WDA) from another EEA country.2097
Wholesaling in Norway based on a relevant authorisation (MIA or WDA) issued within the EU/EEAhttps://legemiddelverket.no/english/import-wholesaling-and-retailing/wholesaling-in-norway-for-the-products-and-facilities-covered-by-the-miaWholesaling in Norway based on a relevant authorisation (MIA or WDA) issued within the EU/EEAHolders of a MIA or a WDA issued within the EU/EEA can perform wholesaler activities in Norway for the products and activities covered by the MIA/WDA. NoMA should be notified when such activities are planned. 1099

​Fant du det du lette etter?